March 03, 2025

Omalizumab Bests Oral Immunotherapy for Food Allergies

"These differences were largely driven by the high rate of adverse events leading to study discontinuation in the OIT-treated participants, despite receiving omalizumab treatment at the initiation of therapy."

Conexiant

June 05, 2024

Do Neighborhood Factors Play a Role in Lung Cancer Aggressiveness?

Investigators have examined whether neighborhood violence may be associated with aggressive lung cancer in Black men, according to new findings presented at the Endocrine Society’s Annual Meeting & Exposition 2024.

Conexiant

June 07, 2024

Study Identifies Subset of Patients With Lung Adenocarcinoma Who Have HER2 Alterations

Researchers have found that a proportion of patients with NSCLC and KRAS, EGFR, or ALK gene mutations may also have HER2 alterations, according to findings presented at the 2024 ASCO Annual Meeting.

The ASCO Post

August 29, 2024

Weekend Sleep Catch-up Slashes Heart Risks: Study

Compensatory weekend sleep linked to 20% lower cardiovascular risk, UK Biobank study of 90,000+ participants reveals.

Conexiant

August 30, 2024

Quit Smoking, Halve Heart Attack Risk: Study

Quitting smoking post-CAD diagnosis cut risk of major cardiovascular events by 44% in international study of over 32,000 patients.

Conexiant

September 17, 2024

Early Smoking Increases Respiratory Risks by Age 28

New study reveals that starting smoking at a young age significantly increases the risk of developing respiratory symptoms in early adulthood.

Conexiant

September 17, 2024

Can Saline Drops Cut Kids' Colds Short?

Hypertonic saline nasal drops shortened children's colds by 2 days and reduced household transmission by 15%, according to a randomized trial.

Conexiant

October 11, 2024

Buzzing Dangers: Ventilation After Bee Stings

Bee venom-related hospitalizations led to mechanical ventilation in 17.4% of cases, with a 71.8-fold increase in mortality risk, according to a new study analyzing over 6,000 admissions.

Conexiant

June 21, 2024

Weight-Loss Drug Zepbound Resolves Sleep Apnea in 52% of Patients: Study

Eli Lilly's weight-loss drug Zepbound showed promise in resolving sleep apnea in up to 52% of patients, according to recent late-stage trial results.

Reuters